Unlocking the Potential of CENP-A Nucleosome Distal (CAD) Centromere Complex as a Drug Target or Biomarker

Target Name: CENP-A-nucleosome distal (CAD) centromere complex

NCBI ID: P16367

CENP-A-nucleosome distal (CAD) centromere complex

Other Name(s): None

Unlocking the Potential of CENP-A Nucleosome Distal (CAD) Centromere Complex as a Drug Target or Biomarker

Introduction

CENP-A nucleosome distal (CAD) centromere complex is a highly conserved complex of proteins that play a critical role in the regulation of gene expression and chromosomal stability. The CENP-A complex is composed of several core proteins, including CENP-A, CENP -B, and CENP-C, which are involved in the recruitment and organization of nucleosomes at the centromere region of chromosomes.

The CENP-A nucleosome distal (CAD) centromere complex is a key regulator of microtubule dynamics and plays a central role in the proper assembly and disassembly of microtubules at the spindle tip. The CENP-A complex is also involved in the regulation of chromatin structure and dynamics, which are critical for the expression of gene regulatory networks.

Despite the significant impact of the CENP-A nucleosome distal (CAD) centromere complex on cellular processes, the study of this complex remains an active area of 鈥嬧?媟esearch, with several studies providing new insights into its functions.

CENP-A Nucleosome Distal (CAD) Centromere Complex as a Drug Target

The CENP-A nucleosome distal (CAD) centromere complex has been identified as a potential drug target due to its involvement in various cellular processes that are important for human health. Several studies have shown that alterations in the CENP-A complex have been associated with various diseases, including cancer, neurodegenerative diseases, and developmental disorders.

One of the key targets of these drugs is the microtubule-associated protein binding partner (MAPB) protein, which is a key component of the CENP-A nucleosome distal (CAD) centromere complex.MAPB is a protein that interacts with the alpha-tubulin protein, which is a key component of microtubules.

Several studies have shown that MAPB interacts with alpha-tubulin and that these interactions play a critical role in the regulation of microtubule dynamics. Also, MAPB has been shown to be a key regulator of the CENP-A nucleosome distal (CAD) centromere complex, which suggests that it may be a potential drug target.

Another potential drug target in the CENP-A nucleosome distal (CAD) centromere complex is the protein SIRT1, which is a NAD+-dependent deoxyribonuclease. SIRT1 is involved in the regulation of various cellular processes, including DNA repair, and has been shown to interact with the CENP-A nucleosome distal (CAD) complex.

Several studies have shown that SIRT1 interacts with the CENP-A nucleosome distal (CAD) complex and that these interactions may play a critical role in the regulation of microtubule dynamics and the proper assembly and disassembly of microtubules at the spindle tip.

CENP-A Nucleosome Distal (CAD) Centromere Complex as a Biomarker

The CENP-A nucleosome distal (CAD) centromere complex is also an attractive biomarker for several diseases, including cancer, neurodegenerative diseases, and developmental disorders. The proper regulation of the CENP-A nucleosome distal (CAD) centromere complex is critical for the proper assembly and disassembly of nucleosomes at the centromere region of chromosomes, which is

Protein Name: CENP-A-nucleosome Distal (CAD) Centromere Complex

The "CENP-A-nucleosome distal (CAD) centromere complex Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CENP-A-nucleosome distal (CAD) centromere complex comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets